Company Research
Whether you are exploring new sales opportunities or researching a new investment, FirstRain provides unique insight into important developments for Abbott Laboratories (ABT). You can receive reports or configure the research engine for yourself.
Report On:
Abbott Laboratories (ABT)
HEALTHCARE - Drugs - Drug Manufacturers - Major
Generated: Thursday September 15, 2011 04:02 AM
|
|
||||||||||||||||||
Quotes About Abbott Laboratories
-
Pfizer Said to Delay Formula Unit Sale as It Weighs Spinoff
We continue to evaluate all structures, obviously with the goal of choosing the structures that will deliver the greatest after-tax value,"
- Frank D'Amelio -
Johnson & Johnson mulls heart device biz
Both [technologies] are interesting. We are interested in looking at them,"
- Dominic Caruso -
Abbott deals beef up late-stage platform of blockbuster contenders
We've had a very aggressive in-licensing effort,"
- John Leonard -
Cystic Fibrosis: Abbott Awards CFCareForward Scholarships to 40 Exceptional Graduate and Undergraduate Students Living with Cystic Fibrosis
During the past 19 years, we've noticed an impressive progression in students with cystic fibrosis applying for scholarships, including some in medical school, law school and overall graduate-level studies,"
- Jim Hynd -
Pfizer Poised to Introduce Blockbuster Arthritis Pill
the new drug may bring in more than $2.6 billion a year,"
- Catherine Arnold
No Comment
-
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
In the U.S., XIENCE PRIME currently is an investigational device and not available for sale. Additional information about XIENCE PRIME is available online at www.abbottvascular.com .
- Charles A. Simonton
-
Beleaguered wipe-maker prepares to reopen
FDA officials have said that H&P Industries is complying with terms of a consent decree, but declined to speculate about a possible date when the firm could reopen.
- msnbc
-
MedImmune sues Abbott over drug development deal
Karen Lancaster, a spokeswoman for MedImmune, declined to comment on the suit Monday.
- Scott Stoffel
Latest Company Intelligence
-
Bay Area Office Buildings on the Block
Developments - The Wall Street Journal | Sep 14,'11
Office giant Shorenstein Properties is seeking to sell two Bay Area office buildings, as landlords put properties on the market amid tremors in the capital markets and broader economy. Jones Lang LaSalle is now marketing for Shorenstein 1400 and 1500 Seaport Boulevard in Redwood City, Calif. according to the brokerage firm. The five-story buildings, totaling 447,000 square feet, are -
Shorenstein puts Pac Shores buildings up for sale
Bay Area BizTalk - Bizjournals | Sep 14,'11
Shorenstein Shorenstein Latest from The Business Journals Real Estate Roundup GLL getting closer to construction at 350 Mission in San Francisco Real Estate Roundup Follow this company Properties is looking to unload two buildings in Redwood City's Pacific Shores development, the latest example of the San Francisco real estate fund manager cashing out its fully-leased, core -
Daily Pharma Watch
GekkoWire | Sep 13,'11
This morning Neurocrine Biosciences announced that Abbott has started a Phase II clinical trial to evaluate elagolix, a next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonist, in the treatment of uterine fibroids. The initiation of this trial triggered a $10 million milestone payment from Abbott to the Company. This morning Spectrum Pharmaceuticals Board of -
Abbott Builds Late-Stage Drug Pipeline With Deals
The Wall Street Journal | Sep 13,'11
Abbott Laboratories' (ABT) drug-discovery arm is focusing on fewer diseases, but it has more promising drug candidates than in recent years partly because of acquisitions and license deals, a top executive said. "We've had a very aggressive in-licensing effort," John Leonard, senior vice president of pharmaceuticals research and development, said in an interview Tuesday. Abbott's -
ETF Spotlight: Health Care Select Sector SPDR Fund (XLV)
ETF Trends | Sep 13,'11
ETF Spotlight on Health Care Select Sector SPDR Fund (NYSEArca: XLV ), part of an ongoing series. Objective: The Health Care Select Sector SPDR Fund tries to reflect the performance of the Health Care Select Sector Index, which includes companies that fall under pharmaceuticals, health care providers & services, health care equipment & supplies, biotechnology, life sciences tools & -
Pepsico: Best Valuation In 30 Years
Seeking Alpha | Sep 12,'11
As defined in several of my previous articles, a ruler stock is one in which earnings, when plotted on a graph, forms a upward sloping straight line, as if drawn with a ruler. In light of my fondness for these types of stocks, I decided to start a series reviewing many of these types of stocks. The following graph illustrates a ruler stock as the green line is the plot of the earnings
FirstRain customers use intelligent business search to find actionable insights about companies, management, and industries. You can review company briefs, quickly research a new idea or opportunity, generate personalized industry reports, or set up alerts on reasons to call. Be sure to view our sample reports below.
